Literature DB >> 28055296

Eradication of melanoma in vitro and in vivo via targeting with a Killer-Red-containing telomerase-dependent adenovirus.

Kiyoto Takehara1,2,3, Shuya Yano1,2,3, Hiroshi Tazawa4, Hiroyuki Kishimoto3, Nobuhiro Narii5, Hiroyuki Mizuguchi5, Yasuo Urata6, Shunsuke Kagawa3, Toshiyoshi Fujiwara3, Robert M Hoffman1,2.   

Abstract

Melanoma is a highly recalcitrant cancer and transformative therapy is necessary for the cure of this disease. We recently developed a telomerase-dependent adenovirus containing the fluorescent protein Killer-Red. In the present report, we first determined the efficacy of Killer-Red adenovirus combined with laser irradiation on human melanoma cell lines in vitro. Cell viability of human melanoma cells was reduced in a dose-dependent and irradiation-time-dependent manner. We used an intradermal xenografted melanoma model in nude mice to determine efficacy of the Killer-Red adenovirus. Intratumoral injection of Killer-Red adenovirus, combined with laser irradiation, eradicated the melanoma indicating the potential of a new paradigm of cancer therapy.

Entities:  

Keywords:  adenovirus; killer-red; melanoma; nude mouse; photodynamic therapy; telomerase

Mesh:

Substances:

Year:  2017        PMID: 28055296      PMCID: PMC5584861          DOI: 10.1080/15384101.2016.1249548

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  36 in total

1.  Matching targets for selective cancer therapy.

Authors:  Mikhail V Blagosklonny
Journal:  Drug Discov Today       Date:  2003-12-15       Impact factor: 7.851

Review 2.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

3.  Fluorescent proteins enhance UVC PDT of cancer cells.

Authors:  Masashi Momiyama; Atsushi Suetsugu; Hiroaki Kimura; Hiroyuki Kishimoto; Ryoichi Aki; Akimitsu Yamada; Harumi Sakurada; Takashi Chishima; Michael Bouvet; Natalia N Bulgakova; Itaru Endo; Robert M Hoffman
Journal:  Anticancer Res       Date:  2012-10       Impact factor: 2.480

Review 4.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

5.  Subcellular imaging in the live mouse.

Authors:  Robert M Hoffman; Meng Yang
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Whole-body imaging with fluorescent proteins.

Authors:  Robert M Hoffman; Meng Yang
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

7.  Biological ablation of sentinel lymph node metastasis in submucosally invaded early gastrointestinal cancer.

Authors:  Satoru Kikuchi; Hiroyuki Kishimoto; Hiroshi Tazawa; Yuuri Hashimoto; Shinji Kuroda; Masahiko Nishizaki; Takeshi Nagasaka; Yasuhiro Shirakawa; Shunsuke Kagawa; Yasuo Urata; Robert M Hoffman; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2014-12-19       Impact factor: 11.454

8.  GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice.

Authors:  Ming-Hsien Tsai; Ryoichi Aki; Yasuyuki Amoh; Robert M Hoffman; Kensei Katsuoka; Hiroaki Kimura; Claudia Lee; Chung-Hsing Chang
Journal:  Anticancer Res       Date:  2010-09       Impact factor: 2.480

9.  Phototoxic effects of fluorescent protein KillerRed on tumor cells in mice.

Authors:  Marina V Shirmanova; Ekaterina O Serebrovskaya; Konstantin A Lukyanov; Ludmila B Snopova; Marina A Sirotkina; Natalia N Prodanetz; Marina L Bugrova; Ekaterina A Minakova; Ilya V Turchin; Vladislav A Kamensky; Sergey A Lukyanov; Elena V Zagaynova
Journal:  J Biophotonics       Date:  2012-06-13       Impact factor: 3.207

10.  Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kei Kawaguchi; Takashi Murakami; Bartosz Chmielowski; Kentaro Igarashi; Tasuku Kiyuna; Michiaki Unno; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2016-11-01
View more
  2 in total

Review 1.  Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment.

Authors:  Hiroshi Tazawa; Kunitoshi Shigeyasu; Kazuhiro Noma; Shunsuke Kagawa; Fuminori Sakurai; Hiroyuki Mizuguchi; Hisataka Kobayashi; Takeshi Imamura; Toshiyoshi Fujiwara
Journal:  Cancer Sci       Date:  2022-04-18       Impact factor: 6.518

Review 2.  Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.

Authors:  Shuya Yano; Hiroshi Tazawa; Hiroyuki Kishimoto; Shunsuke Kagawa; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.